Selective estrogen receptor modulators suppress mesangial cell collagen synthesis

Joel Neugarten, Anjali Acharya, Jun Lei, Sharon Silbiger

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Estrogen receptor modulators (SERMs) are 'designer drugs' that exert estrogen-like actions in some cells but not in others. We examined the effects of the SERMs LY-117018 (an analog of raloxifene) and tamoxifen on mesangial cells synthesis of type I and type IV collagen. We found that LY-117018 and tamoxifen suppressed mesangial cell type IV collagen gene transcription and type IV collagen protein synthesis in a dose-dependent manner, with a potency identical to that of estradiol. Type I collagen synthesis was also suppressed by LY-117018 in a dose-dependent manner with a potency identical to that of estradiol but greater than that of tamoxifen. Genistein, which selectively binds to estrogen receptor-β in nanomolar concentrations, suppressed type I and type IV collagen synthesis, suggesting that estrogen receptor-β mediates the effects of estrogen on collagen synthesis. Because matrix accumulation is central to the development of glomerulosclerosis, second-generation SERMs may prove clinically useful in ameliorating progressive renal disease without the adverse effects of estrogen on reproductive tissues.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Volume279
Issue number2 48-2
StatePublished - 2000

Fingerprint

LY 117018
Selective Estrogen Receptor Modulators
Mesangial Cells
Collagen Type IV
Collagen
Tamoxifen
Collagen Type I
Estrogens
Estrogen Receptors
Estradiol
Designer Drugs
Estrogen Receptor Modulators
Genistein
Kidney
Genes
Proteins

Keywords

  • Angiotensin II
  • Endothelin
  • Estradiol
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. / Neugarten, Joel; Acharya, Anjali; Lei, Jun; Silbiger, Sharon.

In: American Journal of Physiology - Renal Physiology, Vol. 279, No. 2 48-2, 2000.

Research output: Contribution to journalArticle

@article{b493b00d908d4aabbc4b30f7413daee7,
title = "Selective estrogen receptor modulators suppress mesangial cell collagen synthesis",
abstract = "Estrogen receptor modulators (SERMs) are 'designer drugs' that exert estrogen-like actions in some cells but not in others. We examined the effects of the SERMs LY-117018 (an analog of raloxifene) and tamoxifen on mesangial cells synthesis of type I and type IV collagen. We found that LY-117018 and tamoxifen suppressed mesangial cell type IV collagen gene transcription and type IV collagen protein synthesis in a dose-dependent manner, with a potency identical to that of estradiol. Type I collagen synthesis was also suppressed by LY-117018 in a dose-dependent manner with a potency identical to that of estradiol but greater than that of tamoxifen. Genistein, which selectively binds to estrogen receptor-β in nanomolar concentrations, suppressed type I and type IV collagen synthesis, suggesting that estrogen receptor-β mediates the effects of estrogen on collagen synthesis. Because matrix accumulation is central to the development of glomerulosclerosis, second-generation SERMs may prove clinically useful in ameliorating progressive renal disease without the adverse effects of estrogen on reproductive tissues.",
keywords = "Angiotensin II, Endothelin, Estradiol, Transforming growth factor-β",
author = "Joel Neugarten and Anjali Acharya and Jun Lei and Sharon Silbiger",
year = "2000",
language = "English (US)",
volume = "279",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "2 48-2",

}

TY - JOUR

T1 - Selective estrogen receptor modulators suppress mesangial cell collagen synthesis

AU - Neugarten, Joel

AU - Acharya, Anjali

AU - Lei, Jun

AU - Silbiger, Sharon

PY - 2000

Y1 - 2000

N2 - Estrogen receptor modulators (SERMs) are 'designer drugs' that exert estrogen-like actions in some cells but not in others. We examined the effects of the SERMs LY-117018 (an analog of raloxifene) and tamoxifen on mesangial cells synthesis of type I and type IV collagen. We found that LY-117018 and tamoxifen suppressed mesangial cell type IV collagen gene transcription and type IV collagen protein synthesis in a dose-dependent manner, with a potency identical to that of estradiol. Type I collagen synthesis was also suppressed by LY-117018 in a dose-dependent manner with a potency identical to that of estradiol but greater than that of tamoxifen. Genistein, which selectively binds to estrogen receptor-β in nanomolar concentrations, suppressed type I and type IV collagen synthesis, suggesting that estrogen receptor-β mediates the effects of estrogen on collagen synthesis. Because matrix accumulation is central to the development of glomerulosclerosis, second-generation SERMs may prove clinically useful in ameliorating progressive renal disease without the adverse effects of estrogen on reproductive tissues.

AB - Estrogen receptor modulators (SERMs) are 'designer drugs' that exert estrogen-like actions in some cells but not in others. We examined the effects of the SERMs LY-117018 (an analog of raloxifene) and tamoxifen on mesangial cells synthesis of type I and type IV collagen. We found that LY-117018 and tamoxifen suppressed mesangial cell type IV collagen gene transcription and type IV collagen protein synthesis in a dose-dependent manner, with a potency identical to that of estradiol. Type I collagen synthesis was also suppressed by LY-117018 in a dose-dependent manner with a potency identical to that of estradiol but greater than that of tamoxifen. Genistein, which selectively binds to estrogen receptor-β in nanomolar concentrations, suppressed type I and type IV collagen synthesis, suggesting that estrogen receptor-β mediates the effects of estrogen on collagen synthesis. Because matrix accumulation is central to the development of glomerulosclerosis, second-generation SERMs may prove clinically useful in ameliorating progressive renal disease without the adverse effects of estrogen on reproductive tissues.

KW - Angiotensin II

KW - Endothelin

KW - Estradiol

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=0033840243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033840243&partnerID=8YFLogxK

M3 - Article

C2 - 10919851

AN - SCOPUS:0033840243

VL - 279

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 2 48-2

ER -